• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Serotonin Syndrome Risks With Co-Prescription of Triptan Drugs and SSRIs or SNRIs

Serotonin Syndrome Risks With Co-Prescription of Triptan Drugs and SSRIs or SNRIs

September 1, 2018
Adam Strassberg, MD.
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Adam Strassberg, MD. Dr. Strassberg has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Review of: Orlova Y, JAMA Neurology 2018;E1–E7

In 2006, the FDA issued a warning that patients using either selective serotonin reuptake inhibitors or selective norepinephrine reuptake inhibitors (SSRIs or SNRIs) together with triptan antimigraine drugs might be at a heightened risk for serotonin syndrome. Their advisory was based on 27 case reports of suspected serotonin syndrome in people who were prescribed a triptan along with one of these serotonergic antidepressants.

Because migraines are a common comorbidity in depressive and anxiety disorders, many of our patients are co-prescribed these medications. But what is the true risk for serotonin syndrome for these patients?

Yulia Orlova at the University of Florida and colleagues from Boston’s Brigham and Women’s Hospital completed a population-based study to evaluate this risk. They used electronic health records from over 6 million members in the Partners Research Data Registry to identify a cohort of 19,017 patients, who were prescribed both triptans and an SSRI or SNRI between 2001 and 2017, a total of 30,928 person-years of exposure.

Serotonin syndrome was suspected in 17 patients, and concurrent use of triptans and SSRI/SNRI was confirmed in 7 of these. Serotonin syndrome was considered definite in 2 of those cases and possible in the other 5, yielding an incidence rate of 0.6–2.3 cases per 10,000 person-years of exposure.

The rate of co-prescription did not change after the 2006 FDA warning. Between 2001 and 2014, 21%–29% of triptan users were also prescribed an SSRI or SNRI.

TCPR’s Take
Serotonin syndrome is hypothesized to involve activation of only serotonin 2A and 1A receptors. Triptans are primarily agonists for serotonin 1B and 1D receptors and do not activate serotonin 2A or 1A receptors. Thus, we doubt that triptans would increase the risk of serotonin syndrome.

This study supports that conclusion. The risk of serotonin syndrome with concomitant use of triptans and SSRIs or SNRIs appears to be very low. These results cast serious doubt on the validity of the 2006 FDA advisory and suggest that it should be reconsidered.
General Psychiatry
KEYWORDS depressive_disorder research-update
    Adam Strassberg, MD.

    Can Mindfulness-Based Stress Reduction Affect Symptom Outcomes in Older Adults?

    More from this author
    www.thecarlatreport.com
    Issue Date: September 1, 2018
    SUBSCRIBE NOW
    Table Of Contents
    CME Post-Test - Emergency Psychiatry, TCPR, September 2018
    Ask the Editor
    Serotonin Syndrome Risks With Co-Prescription of Triptan Drugs and SSRIs or SNRIs
    Mindfulness Therapy for Adult ADHD
    Benzodiazepines: New Risks for an Old Drug
    Calming Agitated Patients in an Emergency
    The 10 Commandments for Verbal De-Escalation
    DOWNLOAD NOW
    Featured Book
    • MFB7e_Print_App_Access.png

      Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

      The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.